o	Nykode Therapeutics will host a Capital Markets Day on May 12, 2022 from 2
p.m. CET
o	Topics to be discussed will include a comprehensive business update, including
the Company's plans for an uplift to the main market of Oslo Stock Exchange
(Oslo Børs) and insights into Nykode's technology platform 

Oslo, Norway, April 19, 2022 - Nykode Therapeutics AS (Euronext Growth (Oslo):
NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and
development of vaccines and novel immunotherapies, announced today that it will
host a Capital Markets Day for investors and analysts on May 12, 2022 from 2
p.m. CET / 8 a.m. ET. The event will be hosted both with the possibility for
physical attendance at Nykode's facilities in Oslo, Norway, as well as a live
webcast. The Capital Markets Day will feature updates on Nykode's business,
innovations and latest developments.

Further details of the agenda and registration details will follow.


Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of vaccines and novel immunotherapies for the
treatment of cancer and infectious diseases. Nykode's modular vaccine technology
specifically targets antigens to Antigen Presenting Cells, which are essential
for inducing rapid, strong and long-lasting antigen specific immune responses
and eliciting efficacious clinical responses. 

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus 16 induced malignancies which is in Phase 2
for the treatment of cervical cancer